belatacept Injectable Solution

Brand(s)
Nulojix
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
E.R. Squibb & Sons, L.L.C. (2014-09-30)
Oldest Current Product
2011-06-15
License(s)
BLA
RxNORM
INJECTABLE SOLUTION\BELATACEPT
SPL Active
INTRAVENOUS\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\BELATACEPT
SPL Moiety
INTRAVENOUS\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\BELATACEPT

product(s) by strength(s)

belatacept 25 mg/ml injectable solution

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1000030371NulojixBLAE.R. Squibb & Sons, L.L.C.2011-06-15BELATACEPTINTRAVENOUSINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION125288c16ac648-d5d2-9f7d-8637-e2328572754e

application(s)

#idtitleapprovedtradenamesfda division
1125288belatacept Application2011-06-15NulojixCDER

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)
1c16ac648-d5d2-9f7d-8637-e2328572754e (view SPL)These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX. NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011prescriptionHuman PrescriptionE.R. Squibb & Sons, L.L.C.2014-09-305000030371

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII